CA2439528A1 - Cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors - Google Patents

Cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors Download PDF

Info

Publication number
CA2439528A1
CA2439528A1 CA002439528A CA2439528A CA2439528A1 CA 2439528 A1 CA2439528 A1 CA 2439528A1 CA 002439528 A CA002439528 A CA 002439528A CA 2439528 A CA2439528 A CA 2439528A CA 2439528 A1 CA2439528 A1 CA 2439528A1
Authority
CA
Canada
Prior art keywords
alkyl
het
ethyl
terminated
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002439528A
Other languages
English (en)
French (fr)
Inventor
Stephen Martin Denton
Mark Ian Kemp
Sandra Dora Newman
David James Rawson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2439528A1 publication Critical patent/CA2439528A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002439528A 2001-03-16 2002-03-04 Cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors Abandoned CA2439528A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0106661.2A GB0106661D0 (en) 2001-03-16 2001-03-16 Pharmaceutically active compounds
GB0106661.2 2001-03-16
PCT/IB2002/000659 WO2002074774A1 (en) 2001-03-16 2002-03-04 Cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
CA2439528A1 true CA2439528A1 (en) 2002-09-26

Family

ID=9910932

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002439528A Abandoned CA2439528A1 (en) 2001-03-16 2002-03-04 Cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors

Country Status (10)

Country Link
EP (1) EP1368352B1 (enExample)
JP (1) JP2004523585A (enExample)
AT (1) ATE283856T1 (enExample)
BR (1) BR0208154A (enExample)
CA (1) CA2439528A1 (enExample)
DE (1) DE60202134T2 (enExample)
ES (1) ES2231667T3 (enExample)
GB (1) GB0106661D0 (enExample)
MX (1) MXPA03005937A (enExample)
WO (1) WO2002074774A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60237425D1 (de) * 2002-03-28 2010-10-07 Univerzita Palackeho V Olomouc PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE60332387D1 (de) 2002-12-13 2010-06-10 Warner Lambert Co Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
CN100374441C (zh) * 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
BRPI0412259B1 (pt) 2003-07-22 2019-08-20 Astex Therapeutics Limited Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica
WO2005028480A2 (en) * 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
US7485637B2 (en) 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
ES2334578T3 (es) 2005-02-07 2010-03-12 F. Hoffmann-La Roche Ag Fenil-metanonas sustituidas por heterociclo como inhibidores del transportador 1 de la glicina.
KR20080016531A (ko) * 2005-02-18 2008-02-21 서피스 로직스, 인크. 약동학적으로 개선된 화합물
JP2009515984A (ja) 2005-11-15 2009-04-16 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用なアザインダゾール
EP1951668B1 (en) * 2005-11-16 2010-04-14 F.Hoffmann-La Roche Ag Novel process for the preparation of thoc
CN101563348B (zh) * 2006-12-21 2011-08-24 上海特化医药科技有限公司 西地那非的制备方法及其中间体
EP2156833B1 (en) * 2007-05-11 2011-11-30 Santen Pharmaceutical Co., Ltd Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2010026214A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
DK2414363T3 (da) 2009-03-31 2014-01-27 Boehringer Ingelheim Int 1-heterocyklyl-1,5-dihydro-pyrazol[3,4-d]pyrimidin-4-on-derivater og anvendelse af disse som PDE9A-modulatorer.
TWI393578B (zh) 2009-07-07 2013-04-21 Shl Group Ab 注射裝置
WO2012020022A1 (en) 2010-08-12 2012-02-16 Boehringer Ingelheim International Gmbh 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
WO2012143144A1 (en) * 2011-04-21 2012-10-26 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
WO2012143143A1 (en) 2011-04-21 2012-10-26 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
MX2014011115A (es) 2012-03-16 2015-03-13 Axikin Pharmaceuticals Inc Inhibidores de 3,5-diaminopirazol cinasa.
WO2014060112A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
US10000482B2 (en) 2012-10-19 2018-06-19 Origenis Gmbh Kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015091428A1 (en) * 2013-12-20 2015-06-25 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
AU2016355854B2 (en) * 2015-11-16 2021-05-06 Topadur Pharma Ag 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
EA200200240A1 (ru) * 1999-10-11 2002-10-31 Пфайзер Инк. 5-(2-ЗАМЕЩЕННЫЕ-5-ГЕТЕРОЦИКЛИЛСУЛЬФОНИЛПИРИД-3-ИЛ)-ДИГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-7-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ

Also Published As

Publication number Publication date
EP1368352A1 (en) 2003-12-10
ATE283856T1 (de) 2004-12-15
DE60202134D1 (en) 2005-01-05
GB0106661D0 (en) 2001-05-09
EP1368352B1 (en) 2004-12-01
DE60202134T2 (de) 2005-11-24
ES2231667T3 (es) 2005-05-16
JP2004523585A (ja) 2004-08-05
BR0208154A (pt) 2004-03-02
WO2002074774A1 (en) 2002-09-26
MXPA03005937A (es) 2003-09-10

Similar Documents

Publication Publication Date Title
EP1368352B1 (en) Cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors
US6770645B2 (en) Pharmaceutically active compounds
US6756373B1 (en) Pharmaceutically active compounds
CA2387357C (en) Derivatives of pyrazolo[4,3-d]pyrimidin-7-ones which inhibit cyclic guanosine 3',5'-monophosphate phosphodiesterase
EP1372656B1 (en) Pyrazolo[4,3-d]pyrimidinone compounds as cgmp pde inhibitors
US6784185B2 (en) Pharmaceutically active compounds
CA2466824A1 (en) Pde9 inhibitors for treating cardiovascular disorders
EP1395589A1 (en) Imidazo-triazine derivatives as pde 5 inhibitors
US6831074B2 (en) Pharmaceutically active compounds
US6794387B2 (en) Pharmaceutically active compounds
CA2376844A1 (en) Pyrazolo¢4,3-d!pyrimidin-7-ones and pyrazolo¢3,4!pyrimidin-4-ones and purinones which inhibit cgmp pdes
EP1380293A1 (en) Bone metabolism improving agents

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued